奥氮平治疗精神分裂症70例临床分析

Open-label trial of Olanzapine in the treatment of 70 patients with schizophrenia

目的 了解奥氮平治疗精神分裂症的疗效和安全性。方法 对70例精神分裂症病人用奥氮平治疗6周,以阳性和阴性症状量表(PANSS)和简明精神病评定量表(BPRS)评定临床疗效。以副反应量表(TESS)和实验室监测评价安全性。于基线时、实验第1、2、4、6周末分别评定各量表。统计方法为描述性分析和配对t检验。结果 共收集有效病例70例,其中基本痊愈24.2％(17/70),显著进步37.1％(26/70),好转21.4％(15/70)和无效17.1％(12/70)。BPRS总分、PANSS总分、PANSS各分量表分治疗前后比较均有显著性差异(P<0.001)。奥氮平对阳性、阴性症状以及一般精神病症状均有良好疗效。常见副反应为胆碱能作用、嗜睡、体重增加和一过性肝酶升高等。结论 奥氮平是一种安全有效、服用方便的新型抗精神病药物,病人的服药依从性好。

Objectives: The aim of this study is to observe the efficacy and safety of olanzapine in the treatment of schizophrenia. Method: 70 patients with schizophrenia were included in this 6 week open clinical study. The Positive and Negative Syndrome Scale (PANSS) and Brief Psychiatric Rating Scale (BPRS) derived from the PANSS were used to assess the clinical efficacy, the Treatment Emergent Side Effect Scale (TESS) and laboratory tests were used to assess the adverse effects. Scales were evaluated at baseline and the end of week 1, 2, 4, 6. Descriptive analsysis and paired t-test were performed in statistical analysis. Results: 70 valid cases were collected, among the 70 patients, 24. 29% met the criteria of complete relief, 37. 14% significantly improved, 21. 43% improved, and 17.14% got no change. Significant differences existed in total BPRS scores, total PANSS scores and factor scores of PANSS after 6 week treatment of olanzapine. Olanzapine showed good effect on the positive, negative as well as general psy-chopathological symptoms of schizophrenia. The common adverse effects included cholinergic effects, drowsiness, weight gain, and transient increase of liver enzymes. Conclusion: This study suggests that olanzapine is a safe, effective antipsychotic agent with convenient dosing regime and good compliance.